Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma

Multiple Myeloma Clinical Trial

— RCP-MM  

Official title:

Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01572857
• Other study ID #: 201O-AOI354-35
• Status: Completed
• Start date: April 2012
• Est. completion date: April 2018

Study information

• Verified date: September 2018
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The measurement of 24-hour proteinuria allows an assessment of treatment response in patients with multiple myeloma. But it is difficult and restrictive to make.

This study was therefore designed to investigate the correlation between the ratio of proteinuria / creatinine on samples, easier to obtain, and the 24-hour proteinuria in assessing response to this treatment .

Description:

The measure of 24-hour proteinuria is an important biomarker for multiple myeloma.

Multiple myeloma is often accompanied by proteinuria overhead of secretion by plasma cells of large quantities of immunoglobulin free light chains (FLC) kappa or lambda. This proteinuria is composed of monoclonal FLC. The measure of the urinary concentration of FLC is an important biomarker for both diagnosis and evaluation of response to treatment of light chain multiple myeloma but also in intact immunoglobulins multiple myeloma.

The 24-hour proteinuria coupled with urine protein electrophoresis is the standard method for measuring the concentration of urinary FLC. However, it is difficult to obtain a reliable collection of the urine of 24 hours which can make it difficult to assess response to therapy in some patients. It would be interesting to assess proteinuria in a single urine sample collected at any time of day.

Contribution of urinary protein/creatinine ratio for assessment of proteinuria of glomerular origine.

For reasons of convenience, the extent of 24-hour proteinuria was increasingly abandoned by nephrologists in favor of urinary protein/creatinine ratio (UPCR). The use of UPCR measured on a sample of urine overcomes the inaccuracies related to the collection of 24 or variations in urine concentration. This report has been validated against the 24-hour proteinuria for screening or monitoring of renal glomerular diseases by the French Society of Nephrology. In theory, the UPCR is measured on a urine sample, taken preferably in the morning. In practice, the precision of a measurement at any time of day is quite acceptable.

Using the urinary protein/creatinine ratio for assessment of response in multiple myeloma?

The use of UPCR has been validated in patients with renal glomerular disease and especially in diabetic nephropathy. However, the UPCR has not been validated for the assessment of proteinuria overload such as those seen in myeloma. Two recent papers have studied the UPCR in multiple myeloma. The results of these articles suggest:

• That the UPCR is well correlated with the 24-hour proteinuria

• The UPCR varies over time depending on the response to treatment and could therefore be used to monitor patients on treatment

However, given their limits, these two articles do not alow to recommend the widespread use of UPCR instead of the classic 24-hour proteinuria in clinical practice yet. Prospective studies are needed to analyze the correlation between UPCR and proteinuria of 24 hours to assess response to therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• For the first part of the study :

• adult patient

• giving a free, informed and written consent

• patient having a follow-up in the service for multiple myeloma, whatever the age of diagnosis, the isotype of monoclonal component, stage and disease activity

• patient hospitalized in the service whatever the reason for hospitalization (related or not with multiple myeloma)

• proteinuria = 500 mg/24h

• percentage of albuminuria < 50% on urinary protein electrophoresis

• presence of immunoglobulin FLC in immunofixation of urine proteins

• For the second part of the study :

• adult patient

• giving a free, informed and written consent

• patient having a follow-up in the service for multiple myeloma, whatever the age of diagnosis, the isotype of monoclonal component

• requiring the initiation of treatment with chemotherapy

• proteinuria = 500 mg/24h

• percentage of albuminuria < 50% on urinary protein electrophoresis

• presence of immunoglobulin FLC in urine proteins immunofixation

Exclusion Criteria:

• minor patient

• proteinuria < 500 mg/24h

• predominantly glomerular proteinuria with = 50% albumin on urinary protein electrophoresis

• absence of immunoglobulin FLC in urine proteins immunofixation

• progressive urinary infection

• patient with a glomerular nephropathy

• macroscopic hematuria

• patient unable to perform a urinary collection for 24 hours

• patient unable to give a consent

• pregnant or lactating woman

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Proteinuria

Intervention

Biological:
• urinary excretion of FLC immunoglobulin
First phase : Collection of four urine samples daily for 2 days: Of the 24-hour urine at 8 AM at 12 AM at 4 PM On each of these urine samples, the following analysis will be performed: Proteinuria Albuminuria Urinary FLC (Freelite ™) Urine creatinine Second phase: Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row.

Locations

Country	Name	City	State
France	Service de Médecine interne - Hôpital Sud : Rennes University Hospital	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in urinary protein/creatinine ratio	To study the correlation between the urinary protein/creatinine ratio in the sample and 24-hour proteinuria in the assessment of treatment response in patients with multiple myeloma.	Change from baseline in urinary protein/creatinine ratio at 8 AM, 12 AM, 4 PM
Secondary	changes in urinary excretion of FLC	To study the changes in urinary excretion of FLC during the day and night	Of the 24-hour urine, at 8 AM, 12 AM, 4 PM
Secondary	methods for estimating the urinary concentration of FLC	Compare different methods for estimating the urinary concentration of FLC	Of the 24-hour urine, at 8 AM, 12 AM, 4 PM